BioCryst Pharmaceuticals
BCRXBioCryst Pharmaceuticals is a global biotechnology company dedicated to the discovery, development, and commercialization of novel therapies for rare diseases, with a primary focus on hereditary angioedema (HAE).
Earnings
Next report
Nov 2, 2026 (in a month)Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
By net margin
Profile
BioCryst Pharmaceuticals is a global biotechnology company dedicated to the discovery, development, and commercialization of novel therapies for rare diseases, with a primary focus on hereditary angioedema (HAE). The company leverages structure-guided drug design to create first-in-class or best-in-class oral small molecules and injectable protein therapeutics. Its business model integrates an established commercial infrastructure with a pipeline of internal and acquired candidates to drive sustainable growth in high-value rare disease markets.
BioCryst holds a leading position in the HAE market as the provider of the first and only oral prophylactic therapy for both adults and young children.
FAQ
- What is BioCryst Pharmaceuticals's market cap?
- BioCryst Pharmaceuticals (BCRX) has a market capitalization of $2.1B and trades on NASDAQ.
- What is BioCryst Pharmaceuticals's revenue and profitability?
- BioCryst Pharmaceuticals generated $940.6M in trailing twelve-month revenue with a net loss of $384.7M, representing a net margin of -40.9%. Gross margin stands at 97.8%, with free cash flow of $373.4M. The latest reported period is Q2 2026.
- Who are BioCryst Pharmaceuticals's competitors?
- BioCryst Pharmaceuticals's key competitors include Pharvaris, Ionis Pharmaceuticals, BridgeBio Pharma, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does BioCryst Pharmaceuticals partner with?
- BioCryst Pharmaceuticals's notable partners include Pint Pharma GmbH, Neopharmed Gentili, RPI 2019 Intermediate Finance Trust, and others.
- What subsidiaries does BioCryst Pharmaceuticals have?
- BioCryst Pharmaceuticals's subsidiaries include Astria Therapeutics, Inc., Axel Merger Sub, Inc..
- Where is BioCryst Pharmaceuticals headquartered?
- BioCryst Pharmaceuticals is headquartered in United States of America and employs approximately 531 people. It has been publicly traded since 1994.
